Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
RegolamentazioneOne-OffSalute e medicinaEuropa2m
FutuurVerifica disponibilitàDati di risoluzione verificatiProbabilità implicita attuale
No 89%
No 89%Qualità del mercato
33 / 100
Bassa qualitàVolume 24h
—
Liquidità
1,2K €
Bassa liquiditàTrader
4
Commenti
0
Dati di mercato
Aggiornato 2 minuti fa
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsBy 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsEpstein-Barr virus vaccine by 2032?
Manifold MarketsWill the UK propose extending the BBC licence fee to online video in 2026?
KalshiRegole
If, at any point between January 1st, 2026, 00h00 UTC, and December 31st, 2026, 25H59 UTC, the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), or the European Commission authorizes the use or sale of a therapy whose primary mechanism is directly editing the patient's genomic DNA, for any human condition other than sickle cell disease and beta thalassemia, this market will resolve to "Yes".
- Otherwise, it will resolve to "No".
- The Primary Designated Source is the official approval database of whichever regulator is involved — FDA Drug Approvals (fda.gov), MHRA product information (gov.uk/mhra), or the European Commission Union Register of medicinal products (ec.europa.eu/health/documents/community-register).
- Approvals of new indications, formulations, or labels for therapies already approved for sickle cell disease or beta thalassemia (e.g., exa-cel / Casgevy expansions) do not count; only therapies addressing a different human condition.
- Conditional, accelerated, or emergency authorizations from the named regulators docount for this market’s purposes.
- Therapy mechanisms that do not directly edit the patient's genomic DNA in vivo or ex vivo (e.g., mRNA therapies, gene replacement via AAV without genomic editing) do not count.
